It begins with a discussion of the reasons why a biotech company might benefit from entering into a licensing or collaborative arrangement, and then considers the principal legal terms which each type of agreement should contain. One issue to be tackled when spinning out IP into a new company is how to reward key employees in the new venture. European and Member State institutions are trying to improve the business environment and encourage risk capital investors to aid in the establishment of innovative, flexible start-up SMEs. The Israeli biotech industry has struggled in recent years but there are now signs of a revival. A breakthrough technology with real industrial potential is not always enough.
Successful commercialization requires a clear market strategy.
The final part of our serialization of a report from PricewaterhouseCoopers looking at the future of the global healthcare industry. The fourth part of the serialization of a report from PricewaterhouseCoopers looking at the future of the global healthcare industry. The third part of the serialization of a report from PricewaterhouseCoopers looking at the future of the global healthcare industry. The second part of the serialization of a report from PricewaterhouseCoopers looking at the future of the global healthcare industry. The first part of the serialization of a report from PricewaterhouseCoopers looking at the future of the global healthcare industry.